A manager reports a passive stake above 5% in Design Therapeutics (DSGN) across client accounts.
Driehaus Capital Management LLC has reported a passive stake of 5.83% in Design Therapeutics, Inc. (DSGN) across its client accounts. The investment firm beneficially owns 3,650,681 common shares as of September 30, 2026, with shared voting and dispositive power. The shares are held by numerous clients in discretionary accounts, and Driehaus does not know of any single client holding more than 5% of the class.
Design Therapeutics, Inc. SEC Filing (Nov 13, 2026)
Design Therapeutics, Inc. (NASDAQ: DSGN) filed a Notice of Effectiveness with the SEC on November 13, 2026, for a Form S-3 registration statement, which became effective on November 12, 2026, at 9:00 A.M. This filing is available on EDGAR and is rated as having a neutral impact and sentiment by StockTitan's AI analysis. The company's market capitalization is $670.46 million at a $10.47 close, and it is a biotechnology company based in Carlsbad, United States.
Design Therapeutics (DSGN) Stock Price, Chart & Analysis
This article provides a detailed analysis of Design Therapeutics (DSGN) stock, including its latest price, market capitalization, key financial figures, and a "Belegger score." It covers aspects like dividend policy, revenue growth, balance sheet strength, and a valuation assessment based on Peter Lynch's methodology. The report also includes analyst price targets and various future scenarios for the stock's performance.
Design Therapeutics Reports Q3 2026 Results, $208.6 Million in Cash and Securities
Design Therapeutics (DSGN) reported a net loss of $20.3 million for the third quarter of 2026, an increase from $17.0 million a year prior, with research and development expenses rising to $16.9 million. The company maintained a strong financial position with $208.6 million in cash, cash equivalents, and investment securities as of September 30, 2026. Design Therapeutics also provided updates on its clinical programs, including the ongoing Phase 1/2 RESTORE-FA trial for DT-216P2 and Phase 1 trial for DT-818, with data anticipated in 2027.
Design Therapeutics, Inc. Stock 12‑Month Price Target Cut to $21.57, Implies 103% Upside
Design Therapeutics, Inc. (DSGN) has seen its average 12-month price target reduced slightly from $21.71 to $21.57 by analysts, with a range of $19 to $26 per share. This updated target suggests a potential upside of approximately 103% from the Nov. 4 closing price. The consensus rating from 8 covering analysts remains a "Buy."
Design Therapeutics, Inc. (DSGN) Tops Q3 EPS by 2c
Design Therapeutics, Inc. (DSGN) announced its Q3 earnings per share (EPS), reporting ($0.32), which surpassed analyst estimates by $0.02. Analysts had projected an EPS of ($0.34) for the quarter. The company's stock price experienced a decline of 9.03% to $9.67 on the day of the announcement.
With $208.6M in cash and investments, Design Therapeutics (DSGN) posts a wider Q3 loss.
Design Therapeutics (DSGN) reported a wider net loss of $20.3 million in Q3 2026, compared to $17.0 million a year earlier, with operating expenses increasing to $22.2 million. Despite this, the company maintains a strong liquidity position with $208.6 million in cash and investments, which management anticipates will cover requirements for over 12 months. The company also provided positive biomarker and clinical data from its RESTORE-FA trial for DT-216P2, showing dose-dependent increases in FXN levels and improvements in clinical measures for Friedreich ataxia patients.
Form 424B5 Design Therapeutics Inc For: 5 November By Investing.com
The article reports on the filing of Form 424B5 by Design Therapeutics Inc. on November 5. It is a brief announcement from Investing.com and includes the stock symbol DSGN, noting a +2.80% change for the company.
$66.3M sold so far; Design Therapeutics (DSGN) may sell more common stock.
Design Therapeutics, Inc. (DSGN) has disclosed that it may offer and sell up to $200,000,000 in common stock through Jefferies LLC. As of November 4, 2026, the company has already sold $66,330,496.30 worth of shares under a previous sales agreement. The last reported sale price for DSGN common stock was $10.34 per share on November 3, 2026.
Design Therapeutics authorizes $200M stock sales through Jefferies
Design Therapeutics Inc. has authorized an at-the-market (ATM) program to sell up to $200 million in common stock through Jefferies. This new authorization complements an existing $300 million mixed shelf offering, providing the company with flexibility to raise capital for general corporate purposes, including research and development and clinical trials. The ATM program allows for strategic financing based on market conditions, without committing to an immediate sale.
Design Therapeutics Inc. (DSGN) files $300M mixed shelf
Design Therapeutics Inc. (NASDAQ: DSGN) has filed a mixed shelf offering totaling $300,000,000. This offering may include common stock, preferred stock, debt securities, and warrants. The company's current stock price is $10.63, and analysts have an overall "SELL" rating on the stock.
Data from a genetic-disease drug trial are expected after 12 weeks of treatment in early 2027
Design Therapeutics (DSGN) reported its third-quarter 2026 financial results, with a widened net loss of $20.288 million. The company provided updates on its GeneTAC® portfolio, anticipating key clinical readouts in 2027, including 12-week data from the RESTORE-FA trial in Q1 2027 and data from DT-818 and DT-168 trials later in the year. Design Therapeutics ended the quarter with $208.608 million in cash, cash equivalents, and investment securities.
Form 8K Design Therapeutics Inc For: 4 November By Investing.com
This article reports on Design Therapeutics Inc.'s Form 8K filing for November 4th, 2026. The stock symbol for Design Therapeutics Inc. is DSGN, which was up 5.58% at the time of publication. The filing provides important information for investors interested in the company's financial activities and developments.
Design Therapeutics, Inc. (DSGN) Seasonal returns chart
This article displays a seasonal returns chart for Design Therapeutics, Inc. (DSGN) on Yahoo Finance. It shows the average monthly price return for DSGN between 2021 and 2026. The current stock price and daily change are also provided.
Design Therapeutics, Inc. (DSGN) Seasonal returns chart
This article provides a seasonal returns chart for Design Therapeutics, Inc. (DSGN), showing its average monthly price return from 2021 to 2026. As of October 29, the stock was trading at $11.06, down 0.18%.
Friedreich’s Ataxia Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | AbbVie, Minoryx Therapeutics, Takeda, Reata Pharma, Design Therapeutics
This report from DelveInsight outlines the current landscape of Friedreich's Ataxia treatment therapies, detailing over 18 companies and 20 therapies in various stages of clinical development. It highlights key emerging therapies like LX2006, Elamipretide, Omaveloxolone, RT001, Vatiquinone, and Leriglitazone, along with recent clinical trial updates and FDA interactions. The report also covers the market drivers, barriers, and therapeutic assessments, providing insights into the future perspectives of Friedreich's Ataxia treatment.
Design Therapeutics (DSGN) Receives a Buy from Leerink Partners
Leerink Partners has reiterated a Buy rating for Design Therapeutics (DSGN), setting a price target of $22.00. This aligns with a Strong Buy consensus among analysts, with an average price target of $26.11. The company recently reported a GAAP net loss of $20.17 million for the quarter ending June 30.
Wells Fargo Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $26
Wells Fargo has reiterated its Buy rating for Design Therapeutics (DSGN.US), maintaining a target price of $26. This indicates the firm's continued confidence in the company's prospects.
Oppenheimer's fall 2026 SMID-cap ideas include four Strong Buy stocks
Oppenheimer Equity Research has released its Fall 2026 SMID-cap ideas, identifying four "Strong Buy" stocks based on Seeking Alpha's Quant Rating system. Semtech Corporation, Onto Innovation, Life Time Group Holdings, and Pursuit Attractions and Hospitality lead the list with high Quant Ratings, while the remaining nine stocks are rated "Hold." The Quant Rating system assesses valuation, growth, profitability, and momentum to provide a comprehensive stock evaluation.
Design Therapeutics rated 'Hold' as key trial results for Friedreich Ataxia drug await in 2027
Design Therapeutics has received a 'Hold' rating as it awaits key trial results for its lead drug candidate, DT-216P2, targeting Friedreich Ataxia. While early 4-week trial data showed promising improvements, confirmation hinges on 12-week results expected in Q1 2027, with a registrational update planned for Q4 2026. The company is well-funded with over $200 million in cash to advance its GeneTAC platform, facing manageable dilution risk.
Oppenheimer's fall 2026 SMID-cap ideas include four Strong Buy stocks
Oppenheimer Equity Research has released its Fall 2026 SMID-cap ideas, identifying several companies with strong quantitative profiles across various sectors. The list includes four "Strong Buy" stocks based on Seeking Alpha's Quant Rating system: Semtech Corporation (SMTC), Onto Innovation (ONTO), Life Time Group Holdings (LTH), and Pursuit Attractions and Hospitality (PRSU). The remaining nine stocks on the list are rated "Hold."
Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027
Design Therapeutics (DSGN) receives a "Hold" rating as its lead candidate, DT-216P2, targets Friedreich Ataxia (FA). While initial 4-week data from the RESTORE-FA study showed promise, confirmation of efficacy awaits 12-week results in Q1 2027. Upcoming catalysts include a registrational update for DT-216P2 in Q4 2026 and early-stage readouts for other programs in 2027, with the company maintaining a strong cash position.
Wells Fargo Initiates Design Therapeutics at Overweight With $26 Price Target
Wells Fargo has initiated coverage on Design Therapeutics (DSGN) with an "Overweight" rating and set a price target of $26. This assessment comes as Design Therapeutics currently holds an average "buy" rating among analysts, with a mean price target of $21.71. Further details of this report are available through a premium subscription.
Design Therapeutics a new overweight at Wells Fargo on Friedreich ataxia program
Wells Fargo has initiated coverage on Design Therapeutics with an "overweight" rating and a $26 price target, citing the strong potential of its Friedreich ataxia candidate, DT-216P2. The analyst believes the drug could achieve "best-in-disease functional improvement" based on positive early data, projecting peak sales of $1.5 billion globally. DT-216P2 is expected to compete with Biogen's Skyclarys, aiming for significant market share in the FA treatment space.
Wells Fargo Initiates Design Therapeutics at Overweight With $26 Price Target
Wells Fargo has initiated coverage on Design Therapeutics (NASDAQ: DSGN) with an Overweight rating and set a price target of $26. This indicates a positive outlook on the company's stock by the investment bank.
Wells Fargo Initiates Design Therapeutics at Overweight With $26 Price Target
Wells Fargo has initiated coverage on Design Therapeutics (NasdaqGS:DSGN) with an "Overweight" rating and a price target of $26. This announcement follows the company's recent addition to the S&P Biotechnology Select Industry Index and its Q2 earnings report. Design Therapeutics is a biotechnology firm focused on developing GeneTACT molecules for diseases caused by inherited nucleotide repeat expansion mutations, with programs for Friedreich ataxia and Fuchs endothelial corneal dystrophy (FECD).
Design Therapeutics, Inc.(NasdaqGS:DSGN) added to S&P Biotechnology Select Industry Index
Design Therapeutics, Inc. (NasdaqGS:DSGN) has been added to the S&P Biotechnology Select Industry Index. The company is a biotechnology firm focused on developing GeneTACT molecules to treat diseases caused by inherited nucleotide repeat expansion mutations, with programs for Friedreich ataxia and Huntington's Disease. Analysts currently have a "BUY" consensus rating for DSGN, with an average target price of $21.00.
Novartis DM1 miss raises stakes for next wave of DMPK readouts
Novartis' del-desiran failed to meet its primary endpoint in a Phase III trial for myotonic dystrophy type 1, raising questions about its effectiveness and the viability of the DMPK mechanism. While the drug showed activity in secondary endpoints, the miss places increased scrutiny on four upcoming readouts from other DM1 candidates. The full dataset from Novartis' HARBOR study is still pending, which may offer more clarity on the trial's outcomes.
A biotech company's conference chat will be webcast live Sept. 9.
Design Therapeutics (DSGN) announced that its management will participate in a fireside chat at the 2026 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 9, 2026, at 2:45 p.m. ET in New York. A live webcast of the chat will be available on the company's investor relations section of their website, with a replay archived for at least 30 days. The announcement on September 2, 2026, led to a 2.44% increase in DSGN's stock price that day.
Point72 discloses 3.8% Design Therapeutics (DSGN) stake totaling 2.37M shares
Point72 Asset Management, along with Point72 Capital Advisors, Inc. and Steven A. Cohen, has reported a beneficial ownership of 2,366,453 shares of Design Therapeutics, Inc. (DSGN) common stock, which represents 3.8% of the class, as of June 30, 2026. The filing indicates that while they hold shared voting and dispositive power over these shares through an investment fund, they do not claim sole power. This disclosure, made via an amended SCHEDULE 13G/A, confirms their ownership is 5 percent or less of the company.
Design Therapeutics (DSGN): Sirenia Capital discloses 9.5% beneficial ownership stake
Sirenia Capital Management LP and Alex Silverstein have reported a 9.5% beneficial ownership stake in Design Therapeutics, Inc. (DSGN), totaling 5,963,936 shares, which includes shares issuable from call options. This disclosure was made in a Schedule 13G filing, indicating a passive investment purpose rather than an intent to influence control. The filing details shared voting and dispositive power over these shares, with SILV Fund, Ltd. also having rights to dividends or sale proceeds from over 5% of the outstanding common stock.
Design Therapeutics, Inc. $DSGN Shares Bought by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP significantly increased its stake in Design Therapeutics (NASDAQ:DSGN) by 45.0% in Q1, now owning 431,840 shares valued at $4.59 million. Other institutional investors also adjusted their holdings in the company. Design Therapeutics reported better-than-expected Q2 earnings and has an average "Moderate Buy" rating from analysts with an average price target of $16.50.
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Rating of "Moderate Buy" by Brokerages
Design Therapeutics, Inc. (NASDAQ:DSGN) has received a "Moderate Buy" consensus rating from eight brokerages, with an average 12-month price target of $16.50. The stock recently opened at $14.33, trading above its 50-day and 200-day moving averages, and institutional investors own over 56% of the company. The biopharmaceutical company focuses on developing small molecule therapeutic drugs for genetic diseases using its GeneTAC platform.
Design Therapeutics, Inc. $DSGN Shares Purchased by Sei Investments Co.
Sei Investments Co. significantly increased its stake in Design Therapeutics, Inc. (NASDAQ:DSGN) by 152.6% in the first quarter, now holding 133,203 shares valued at approximately $1.42 million. Institutional investors collectively own 56.64% of the company. Despite reporting a quarterly EPS of negative $0.32, beating estimates, the stock carries a "Moderate Buy" consensus rating from analysts with an average price target of $16.50.
Design Therapeutics Inc (DSGN) Earnings Forecast: Future EPS & Revenue Growth Estimates
The article provides an earnings forecast for Design Therapeutics Inc (DSGN), noting its current earnings forecast score is 8.86, ranking 47 out of 387 in its industry. Analysts have set an average price target of $12.50, with a majority recommending a "Buy" for the stock. The company's previous quarter's EPS was -$0.29, beating the market expectation of -$0.32, and the next quarter's EPS is projected to be -$0.36.
Renaissance Technologies LLC Buys 121,100 Shares of Design Therapeutics, Inc. $DSGN
Renaissance Technologies LLC increased its stake in Design Therapeutics, Inc. (NASDAQ:DSGN) by 42.2% in the first quarter, purchasing an additional 121,100 shares, bringing its total holdings to 408,200 shares valued at approximately $4.34 million. Other institutional investors have also adjusted their positions in the company, which currently has 56.64% institutional ownership. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $16.50, and the company recently beat quarterly earnings estimates.
Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $22
Craig-Hallum has reiterated its Buy rating for Design Therapeutics (DSGN.US) and maintained its target price at $22. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Design Therapeutics Reports $20.2 Million Q2 Net Loss, Updates RESTORE-FA Trial
Design Therapeutics reported a net loss of $20.2 million for Q2 2024, down from $25.2 million in the same period last year. The company provided an update on its RESTORE-FA Phase 1b clinical trial for Friedreich's ataxia, noting positive clinical data continues to emerge. They anticipate presenting results from the 28-day multiple ascending dose portion of the trial in Q4 2024.
Design Therapeutics : Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
Design Therapeutics announced updates on its RESTORE-FA clinical program, modifying the trial to focus on a 1 mpk dose with 12-week data expected in Q1 2027. The company also initiated dosing for its DT-818 in a Phase 1 trial for myotonic dystrophy type 1 and reported second quarter 2026 financial results, including a net loss of $20.2 million and a strong cash position of $207.4 million. Delays in DT-168 supply pushed FECD data to 2027, while preclinical work continues for Huntington's disease.
Design Therapeutics Q2 Net Loss Narrows
Design Therapeutics reported a narrowed net loss for the second quarter, although it did not provide specific figures in the provided document. The company's financial performance indicates an improvement in its loss compared to the previous period.
8-K: Design Therapeutics | 8-K: Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
This 8-K filing from Design Therapeutics provides an update on the RESTORE-FA clinical development program. Additionally, the company reported its financial results for the second quarter of 2026.
Design Therapeutics, Inc. 2Q 2026: Net loss $(20,165)K, EPS $(0.32) — 10-Q Summary
Design Therapeutics, Inc. (DSGN) reported a net loss of $(20,165)K and diluted EPS of $(0.32) for Q2 2026, with cash and investments totaling $207.4M, providing over 12 months of runway. The company highlighted clinical progress in its RESTORE-FA Phase 1/2 trial, pipeline expansion across multiple disease areas, and favorable safety profiles for its drug candidates. An improved formulation of DT-216 (P2) also showed better human pharmacokinetics, leading to a modified trial design and registrational planning.
Design Therapeutics posts Q2 loss, updates clinical trials
Design Therapeutics Inc. reported a net loss of $20.2 million for Q2 2026, or $0.32 per share, with total cash and investments at $207.4 million. The company updated its RESTORE-FA trial for Friedreich ataxia, specifying endogenous blood FXN protein percent change as the primary efficacy endpoint and exploring a higher dose. It also initiated a Phase 1 trial for myotonic dystrophy type 1 and expects data for its Fuchs endothelial corneal dystrophy trial in 2027 due to supply delays.
Design Therapeutics Reports $20.2 Million Q2 Net Loss, Updates RESTORE-FA Trial
Design Therapeutics (DSGN) reported a Q2 2026 net loss of $20.2 million, with $207.4 million in cash, cash equivalents, and investment securities at quarter-end. The company also provided updates on its GeneTAC clinical pipeline, including modifications to the RESTORE-FA trial for DT-216P2 in Friedreich ataxia, with registrational plans expected in Q4 2026 and 12-week treatment data in Q1 2027. Additionally, patient dosing has begun for DT-818 in myotonic dystrophy type 1, and data for both DT-818 and DT-168 in Fuchs endothelial corneal dystrophy are anticipated in 2027.
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
Design Therapeutics reported its second-quarter 2026 financial results and provided updates on its clinical programs. The company highlighted progress in its RESTORE-FA trial for Friedreich ataxia, initiating patient dosing for DT-818 in myotonic dystrophy type 1, and advancing preclinical work for Huntington's disease. Design Therapeutics ended the quarter with $207.4 million in cash and securities, providing a strong financial runway.
Design Therapeutics reports $20.2M Q2 net loss, $207.4M cash as RESTORE-FA advances
Design Therapeutics reported a net loss of $20.2 million for Q2 2026, holding $207.4 million in cash, cash equivalents, and investment securities. The company provided updates on its clinical programs, including the advancement of RESTORE-FA (DT-216P2) with an expected registrational plan update in Q4 2026 and initiation of a Phase 1 trial for DT-818 in myotonic dystrophy type 1. Other programs like DT-168 for Fuchs endothelial corneal dystrophy faced minor delays.
DSGN|Design Therapeutics Inc|Price:11.860|Chg%:-0.020
This article provides a comprehensive stock analysis of Design Therapeutics Inc (DSGN) by TradingKey. It highlights the company's relatively weak fundamentals but high growth potential, with its valuation considered fairly valued within the Biotechnology & Medical Research industry. Despite institutional confidence and a strong "Buy" rating from multiple analysts, the stock has shown weak market performance and is expected to trend down in the medium term, trading sideways between support and resistance levels.
Design Therapeutics Inc (DSGN) Institutional Confidence
Design Therapeutics Inc (DSGN) has an institutional shareholding score of 5.00, placing it 132nd out of 385 companies in the Biotechnology & Medical Research industry. The institutional shareholding proportion recently decreased by 8.26% quarter-over-quarter to 61.89%. Steven Cohen is the largest institutional shareholder, holding 2.61 million shares, which represents 4.36% of the shares outstanding, despite a 14.84% decrease in his holdings.
Design Therapeutics Inc (DSGN) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Design Therapeutics Inc (DSGN), highlighting its current earnings forecast score of 8.86 and an average price target of $12.50 based on 7 analyst ratings. Most analysts rate DSGN as a "Buy" for its stock. The report also includes past and projected EPS figures and a peer comparison within the Biotechnology & Medical Research industry.
Design Therapeutics Inc (DSGN) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Design Therapeutics Inc (DSGN), detailing various financial metrics related to volatility, drawdown, and liquidity. Key figures include a Beta vs S&P 500 index of 1.66, a 240-Day Volatility of +84.43%, and a 5-year maximum drawdown of +92.22%. The report highlights both positive and negative daily returns over different periods, offering insights into the stock's historical performance and risk profile.